Blood CancerArchives
Daratumumab/Bortezomib/Thalidomide/Dexamethasone in Newly Diagnosed Myeloma: CASSIOPEIA Minimal Residual Disease Results
Blood Cancer 1 min.
Previous results from CASSIOPEIA (NCT02541383) demonstrated superior progression-free survival (PFS) and minimal residual disease (MRD) negativity with the addition of daratumumab to bortezomib, thalidomide, and dexamethasone (VTd) induction/consolidation and with daratumumab maintenance versus observation...
Synthetic bone marrow images augment real samples in developing acute myeloid leukemia microscopy classification models
Blood Cancer 6 min.
The term “big data” has become a buzzword in medical literature, yet its interpretation varies significantly between medical professionals and data scientists. For instance, ImageNet1 (https://www.image-net.org/)—an object-based image database frequently used for training and validation...
Real-World Experience with Venetoclax Treatment for Newly-Diagnosed Acute Myeloid Leukemia in Japan (VENUS Study): An Interim Analysis Focusing on Neutropenia Management
Blood Cancer 3 min.
The small molecule selective inhibitor of B-cell lymphoma-2 (BCL-2), venetoclax [1], was approved in Japan in 2021 with azacitidine (VEN/AZA) or low-dose cytarabine (VEN/LDAC) for acute myeloid leukemia (AML) [2]. Despite significantly improving AML outcomes versus a hypomethylating agent (HMA) or low-dose...
An 8-year-old girl with secondary histiocytic sarcoma with BRAFV600 mutation following T-cell acute lymphoblastic leukemia demonstrating stable disease for 3 years on dabrafenib and trametinib – a case report and literature review
Blood Cancer 3 min.
Histiocytic sarcoma (HS) developing as a secondary neoplasm is extraordinarily rare [1] in childhood and presents a diagnostic challenge. Dismal prognosis is expected due to rapid progression and poor response to therapy [2]. No optimal treatment has been defined and standardized [3]. Among the reported...
Prediction of survival in acute myeloid leukemia patients by extracellular to intracellular water ratio and sarcopenia: development and validation of a novel nomogram
Blood Cancer 7 min.
Acute myeloid leukemia (AML), a heterogeneous hematologic malignancy marked by abnormal proliferation of myeloid blasts or progranulocytes lacking differentiation, is the most common acute leukemia in adults and the leading cause of leukemia-related deaths globally. Outcomes for patients with AML are...
